Company intelligence / Profile preview

Koliber Biosciences

San Diego, California, United Stateskoliberbio.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

Koliber Biosciences develops AI-driven platforms and genome engineering toolkits to accelerate drug discovery—especially peptide drugs—and engineer probiotic/microbiome strains. Their work includes machine learning models trained on biological data to design genetic control elements and robust DNA delivery methods. The company has received NIH NIGMS and NSF SBIR grants supporting their technology development but has not reported clinical results or advanced therapeutic candidates as of June 2025.[1][3]

Therapeutic areas: OtherInfectious Diseases
Modalities: PeptidesSmall moleculeGenome engineering toolsAI/machine learning platform
Industry: Drug Discovery Services

Partnerships

National Institutes of Health NIGMS (grant funding)National Science Foundation SBIR programSynBioBeta SF2015 event participation/recognition

Beyond the preview

Go deeper on Koliber Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Koliber Biosciences.

Explore the full profile